# Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

> **NCT07016399** · PHASE2 · RECRUITING · sponsor: **Vandana Abramson** · enrollment: 51 (estimated)

## Conditions studied

- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Triple-Negative Breast Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Breast Biopsy Procedure
- **DRUG:** Carboplatin
- **DRUG:** Cyclophosphamide
- **DRUG:** Darolutamide
- **DRUG:** Doxorubicin
- **DRUG:** Epirubicin
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Surgical Procedure
- **PROCEDURE:** Ultrasound Imaging

## Key facts

- **NCT ID:** NCT07016399
- **Lead sponsor:** Vandana Abramson
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-09
- **Primary completion:** 2028-09-01
- **Final completion:** 2033-10
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2025-10-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07016399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07016399, "Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07016399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*